Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ancor Capital Partners has acquired WellSpring Pharmaceutical, which manufactures specialty prescription and over-the-counter (OTC) products in North America.
Subscribe to our email newsletter
Ancor joined Sentinel Capital and Yukon Capital to complete the transaction.
Ancor Capital Partners managing partner J Randall Keene said WellSpring represents the 15th acquisition of a healthcare company for Ancor and combines their experience in contract manufacturing, pharmaceutical sales and OTC products.
"We are very pleased to have teamed with Sentinel and Yukon on this acquisition," Keene added.
WellSpring Pharmaceutical Chief Financial Officer and Chief Operating Officer Wendy Shusko said under Ancor and Sentinel, the company can achieve the aggressive growth opportunities in the market.